

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8847788/publications.pdf>

Version: 2024-02-01

132
papers

9,820
citations

94381

37
h-index

36008

97
g-index

134
all docs

134
docs citations

134
times ranked

9526
citing authors

#	ARTICLE	IF	CITATIONS
1	Editorial commentary: Adequate blood pressure control unattainable without adequate recognition and treatment of primary aldosteronism. <i>Trends in Cardiovascular Medicine</i> , 2022, 32, 234-236.	2.3	3
2	Poor self-reported sleep is associated with risk factors for cardiovascular disease: A cross-sectional analysis in half a million adults. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13738.	1.7	7
3	Interplay between mineral bone disorder and cardiac damage in acute kidney injury: from Ca ²⁺ mishandling and preventive role of Klotho in mice to its potential mortality prediction in human. <i>Translational Research</i> , 2022, 243, 60-77.	2.2	5
4	Unilateral Acute Renal Ischemia-Reperfusion Injury Induces Cardiac Dysfunction through Intracellular Calcium Mishandling. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2266.	1.8	7
5	Diabetes, Hypertension, and the Mediating Role of Lifestyle: A Cross-Sectional Analysis in a Large Cohort of Adults. <i>American Journal of Preventive Medicine</i> , 2022, 63, e21-e29.	1.6	4
6	Physical Exercise in Resistant Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, .	1.1	8
7	Lifestyle interventions for the prevention and treatment of hypertension. <i>Nature Reviews Cardiology</i> , 2021, 18, 251-275.	6.1	128
8	Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes. <i>Circulation</i> , 2021, 143, 540-552.	1.6	171
9	The year in cardiovascular medicine 2020: epidemiology and prevention. <i>European Heart Journal</i> , 2021, 42, 813-821.	1.0	18
10	TWEAK as a common pathway in the heart and the kidneys in cardiorenal syndrome. <i>Journal of Pathology</i> , 2021, 254, 5-19.	2.1	7
11	An Overview of FGF-23 as a Novel Candidate Biomarker of Cardiovascular Risk. <i>Frontiers in Physiology</i> , 2021, 12, 632260.	1.3	39
12	TCA Cycle and Fatty Acids Oxidation Reflect Early Cardiorenal Damage in Normoalbuminuric Subjects with Controlled Hypertension. <i>Antioxidants</i> , 2021, 10, 1100.	2.2	6
13	Early renal and vascular damage within the normoalbuminuria condition. <i>Journal of Hypertension</i> , 2021, 39, 2220-2231.	0.3	7
14	Cardiovascular Risk Stratification Based on Oxidative Stress for Early Detection of Pathology. <i>Antioxidants and Redox Signaling</i> , 2021, 35, 602-617.	2.5	9
15	Digital therapeutics and lifestyle: the start of a new era in the management of arterial hypertension?. <i>European Heart Journal</i> , 2021, 42, 4123-4125.	1.0	4
16	Preventing and managing hypertension: do not forget the night. <i>Hypertension Research</i> , 2021, 44, 1674-1675.	1.5	4
17	Analysis of Global Oxidative Status Using Multimarker Scores Reveals a Specific Association Between Renal Dysfunction and Diuretic Therapy in Older Adults. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, 1198-1205.	1.7	4
18	Acute Aerobic Exercise Induces Short-Term Reductions in Ambulatory Blood Pressure in Patients With Hypertension: A Systematic Review and Meta-Analysis. <i>Hypertension</i> , 2021, 78, 1844-1858.	1.3	13

#	ARTICLE	IF	CITATIONS
19	Fibroblast Growth Factor-23-Klotho Axis in Cardiorenal Syndrome: Mediators and Potential Therapeutic Targets. <i>Frontiers in Physiology</i> , 2021, 12, 775029.	1.3	5
20	Resistant hypertension: new insights and therapeutic perspectives. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 188-193.	1.4	18
21	Prediction of the early response to spironolactone in resistant hypertension by the combination of matrix metalloproteinase-9 activity and arterial stiffness parameters. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, , .	1.4	0
22	Genetic Deletion of NOD1 Prevents Cardiac Ca ²⁺ Mishandling Induced by Experimental Chronic Kidney Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8868.	1.8	5
23	Oxidized Low-Density Lipoprotein Associates with Ventricular Stress in Young Adults and Triggers Intracellular Ca ²⁺ Alterations in Adult Ventricular Cardiomyocytes. <i>Antioxidants</i> , 2020, 9, 1213.	2.2	7
24	Exercise Reduces Ambulatory Blood Pressure in Patients With Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Journal of the American Heart Association</i> , 2020, 9, e018487.	1.6	60
25	Urinary metabolic signatures reflect cardiovascular risk in the young, middle-aged, and elderly populations. <i>Journal of Molecular Medicine</i> , 2020, 98, 1603-1613.	1.7	10
26	Enhanced Klotho availability protects against cardiac dysfunction induced by uraemic cardiomyopathy by regulating Ca ²⁺ handling. <i>British Journal of Pharmacology</i> , 2020, 177, 4701-4719.	2.7	24
27	Differential metabolic profile associated with the condition of normoalbuminuria in the hypertensive population. <i>Nefrologia</i> , 2020, 40, 439-445.	0.2	3
28	Prevalence of office and ambulatory hypotension in treated hypertensive patients with coronary disease. <i>Hypertension Research</i> , 2020, 43, 696-704.	1.5	3
29	Novel molecular plasma signatures on cardiovascular disease can stratify patients throughout life. <i>Journal of Proteomics</i> , 2020, 222, 103816.	1.2	5
30	Renin-angiotensin system inhibitors in the COVID-19 pandemic: consequences of antihypertensive drugs. <i>European Heart Journal</i> , 2020, 41, 2067-2069.	1.0	13
31	Blood pressure targets in patients with chronic kidney disease: MDRD and AASK now confirming SPRINT. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 287-290.	1.4	5
32	Beneficial effects of paricalcitol on cardiac dysfunction and remodelling in a model of established heart failure. <i>British Journal of Pharmacology</i> , 2020, 177, 3273-3290.	2.7	10
33	Perfil metabólico diferenciador asociado a la condición de normoalbuminuria en la población hipertensa. <i>Nefrologia</i> , 2020, 40, 440-445.	0.2	2
34	Finerenone Reduces Intrinsic Arterial Stiffness in Munich Wistar Kuntze Rats, a Genetic Model of Chronic Kidney Disease. <i>American Journal of Nephrology</i> , 2020, 51, 294-303.	1.4	29
35	On the need of the simultaneous control of arterial hypertension and diabetes mellitus. <i>Journal of Clinical Hypertension</i> , 2020, 22, 221-222.	1.0	0
36	Muscling in on Resistant Hypertension. <i>Circulation</i> , 2020, 141, 240-242.	1.6	1

#	ARTICLE	IF	CITATIONS
37	Prognostic Relevance of Short-Term Blood Pressure Variability. Hypertension, 2020, , HYPERTENSIONAHA11914508.	1.3	3
38	Association of clinic and ambulatory heart rate parameters with mortality in hypertension. Journal of Hypertension, 2020, 38, 2416-2426.	0.3	10
39	The endless story of markers of renal function and cardiovascular risk. European Heart Journal, 2019, 40, 3494-3495.	1.0	3
40	Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. American Journal of Nephrology, 2019, 50, 345-356.	1.4	127
41	Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. American Journal of Nephrology, 2019, 50, 333-344.	1.4	112
42	Monotherapy still useful in a bunch of patients with arterial hypertension. International Journal of Cardiology, 2019, 291, 119-120.	0.8	0
43	Frequency and Prognosis of Treated Hypertensive Patients According to Prior and New Blood Pressure Goals. Hypertension, 2019, 74, 130-136.	1.3	12
44	Oxidative Status before and after Renal Replacement Therapy: Differences between Conventional High Flux Hemodialysis and on-Line Hemodiafiltration. Nutrients, 2019, 11, 2809.	1.7	13
45	Identification of six cardiovascular risk biomarkers in the young population: A promising tool for early prevention. Atherosclerosis, 2019, 282, 67-74.	0.4	14
46	Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints. European Heart Journal, 2019, 40, 880-886.	1.0	34
47	Hypertension in Diabetic Kidney Disease. , 2019, , 325-335.		1
48	Urine Haptoglobin and Haptoglobin-Related Protein Predict Response to Spironolactone in Patients With Resistant Hypertension. Hypertension, 2019, 73, 794-802.	1.3	6
49	Relationship between Clinic and Ambulatory Blood-Pressure Measurements and Mortality. New England Journal of Medicine, 2018, 378, 1509-1520.	13.9	420
50	Translational science in albuminuria: a new view of de novo albuminuria under chronic RAS suppression. Clinical Science, 2018, 132, 739-758.	1.8	4
51	<sc>PTH</sc>, vitamin D, and the <sc>FGF</sc>â€”klotho axis and heart: Going beyond the confines of nephrology. European Journal of Clinical Investigation, 2018, 48, e12902.	1.7	35
52	White-coat UnControlled Hypertension, Masked UnControlled Hypertension, and True UnControlled Hypertension, phonetic and mnemonic terms for treated hypertension phenotypes. Journal of Hypertension, 2018, 36, 446-447.	0.3	12
53	Prevalence of Masked Hypertension in Untreated and Treated Patients With Office Blood Pressure Below 130/80 mmâ€™Hg. Circulation, 2018, 137, 2651-2653.	1.6	33
54	Potential role of new molecular plasma signatures on cardiovascular risk stratification in asymptomatic individuals. Scientific Reports, 2018, 8, 4802.	1.6	8

#	ARTICLE	IF	CITATIONS
55	New vascular biomarkers related to ABPM phenotypes in untreated patients. <i>Journal of Clinical Hypertension</i> , 2018, 21, 53-54.	1.0	0
56	Prognostic Value of Masked Uncontrolled Hypertension. <i>Hypertension</i> , 2018, 72, 862-869.	1.3	94
57	Ambulatory Blood Pressure and Mortality. <i>New England Journal of Medicine</i> , 2018, 379, 1285-1288.	13.9	5
58	The epidemiological magnitude of white-coat hypertension and masked hypertension in Africa. <i>Journal of Clinical Hypertension</i> , 2018, 20, 1173-1175.	1.0	0
59	Exercise benefits in cardiovascular disease: beyond attenuation of traditional risk factors. <i>Nature Reviews Cardiology</i> , 2018, 15, 731-743.	6.1	449
60	Blood pressure reduction in diabetes: lessons from ACCORD, SPRINT and EMPA-REG OUTCOME. <i>Nature Reviews Endocrinology</i> , 2017, 13, 365-374.	4.3	29
61	A review of chemical therapies for treating diabetic hypertension. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 909-923.	0.9	8
62	Has the SPRINT trial introduced a new blood-pressure goal in hypertension?. <i>Nature Reviews Cardiology</i> , 2017, 14, 560-565.	6.1	19
63	Renin-angiotensin system blockade: Finerenone. <i>Nephrologie Et Therapeutique</i> , 2017, 13, S47-S53.	0.2	17
64	Sacubitril/valsartan in the treatment of arterial hypertension: an unaccomplished promise?. <i>Hypertension Research</i> , 2017, 40, 439-440.	1.5	2
65	Clinic Versus Daytime Ambulatory Blood Pressure Difference in Hypertensive Patients. <i>Hypertension</i> , 2017, 69, 211-219.	1.3	30
66	Immune system deregulation in hypertensive patients chronically RAS suppressed developing albuminuria. <i>Scientific Reports</i> , 2017, 7, 8894.	1.6	13
67	Prevalence and clinical characteristics of white-coat hypertension based on different definition criteria in untreated and treated patients. <i>Journal of Hypertension</i> , 2017, 35, 2388-2394.	0.3	43
68	Prevalence and Clinical Characteristics of Refractory Hypertension. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	54
69	Progression of Renal Insufficiency in Patients with Essential Hypertension Treated with Renin Angiotensin Aldosterone System Blockers: An Electrocardiographic Correlation. <i>Diseases (Basel)</i> , 2017, 9, 104.	0.784314	0
70	Rapid, Automated, and Specific Immunoassay to Directly Measure Matrix Metalloproteinase-9 Tissue Inhibitor of Metalloproteinase-1 Interactions in Human Plasma Using AlphaLISA Technology: A New Alternative to Classical ELISA. <i>Frontiers in Immunology</i> , 2017, 8, 853.	2.2	14
71	Kalirin and CHD7: novel endothelial dysfunction indicators in circulating extracellular vesicles from hypertensive patients with albuminuria. <i>Oncotarget</i> , 2017, 8, 15553-15562.	0.8	20
72	Urinary exosomes reveal protein signatures in hypertensive patients with albuminuria. <i>Oncotarget</i> , 2017, 8, 44217-44231.	0.8	33

#	ARTICLE	IF	CITATIONS
73	SPRINT. Counteracting the risk of prehypertension?. Journal of the American Society of Hypertension, 2016, 10, 546-547.	2.3	1
74	New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval. International Journal of Cardiology, 2016, 216, 46-51.	0.8	20
75	Global cardiovascular protection in chronic kidney disease. Nature Reviews Cardiology, 2016, 13, 603-608.	6.1	36
76	Ambulatory blood pressure monitoring in daily clinical practice – the Spanish <sc>ABPM</sc> Registry experience. European Journal of Clinical Investigation, 2016, 46, 92-98.	1.7	35
77	New Strategy to Control Blood Pressure: Interactive Mobile Phone Support. Journal of Clinical Hypertension, 2016, 18, 109-110.	1.0	1
78	Hypertensive patients exhibit an altered metabolism. A specific metabolite signature in urine is able to predict albuminuria progression. Translational Research, 2016, 178, 25-37.e7.	2.2	28
79	Association Between High and Very High Albuminuria and Nighttime Blood Pressure: Influence of Diabetes and Chronic Kidney Disease. Diabetes Care, 2016, 39, 1729-1737.	4.3	26
80	Role of matrix metalloproteinase-9 in chronic kidney disease: a new biomarker of resistant albuminuria. Clinical Science, 2016, 130, 525-538.	1.8	48
81	Ambulatory blood pressure in hypertensive patients with inclusion criteria for the SPRINT trial. Journal of the American Society of Hypertension, 2016, 10, 947-953.e5.	2.3	22
82	Plasma Molecular Signatures in Hypertensive Patients With Renin–Angiotensin System Suppression. Hypertension, 2016, 68, 157-166.	1.3	18
83	Urinary alpha-1 antitrypsin and CD59 glycoprotein predict albuminuria development in hypertensive patients under chronic renin-angiotensin system suppression. Cardiovascular Diabetology, 2016, 15, 8.	2.7	24
84	Comparison of application of different methods to estimate lifetime cardiovascular risk. European Journal of Preventive Cardiology, 2016, 23, 564-571.	0.8	8
85	Short-term and Long-term Reproducibility of Hypertension Phenotypes Obtained by Office and Ambulatory Blood Pressure Measurements. Journal of Clinical Hypertension, 2016, 18, 927-933.	1.0	38
86	Biomarkers of renal injury and function: diagnostic, prognostic and therapeutic implications in heart failure. European Heart Journal, 2016, 37, 2577-2585.	1.0	82
87	Ambulatory and home blood pressure monitoring in people with chronic kidney disease. Time to abandon clinic blood pressure measurements?. Current Opinion in Nephrology and Hypertension, 2015, 24, 488-491.	1.0	5
88	KLK1 and ZG16B proteins and arginine–proline metabolism identified as novel targets to monitor atherosclerosis, acute coronary syndrome and recovery. Metabolomics, 2015, 11, 1056-1067.	1.4	35
89	Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials. European Heart Journal, 2015, 36, 1967-1973.	1.0	87
90	An update of the blockade of the renin angiotensin aldosterone system in clinical practice. Expert Opinion on Pharmacotherapy, 2015, 16, 2283-2292.	0.9	26

#	ARTICLE	IF	CITATIONS
91	Prediction of development and maintenance of high albuminuria during chronic renin-angiotensin suppression by plasma proteomics. <i>International Journal of Cardiology</i> , 2015, 196, 170-177.	0.8	18
92	LCZ696, The Need for an Indication in Arterial Hypertension. <i>American Journal of Hypertension</i> , 2015, 28, 1403-1404.	1.0	2
93	Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 884.	3.8	523
94	Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: time for re-evaluation?. <i>Kidney International</i> , 2014, 85, 536-546.	2.6	64
95	Blood Pressure and Uric Acid in Diabetes Mellitus. <i>Journal of Clinical Hypertension</i> , 2014, 16, 269-269.	1.0	1
96	Hypertension and Obesity: Correlates With Renin-Angiotensin-Aldosterone System and Uric Acid. <i>Journal of Clinical Hypertension</i> , 2014, 16, 559-560.	1.0	14
97	Usefulness of ambulatory blood pressure monitoring (ABPM) in daily clinical practice: Data from the Spanish ABPM registry. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2014, 41, 30-36.	0.9	8
98	European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. <i>Journal of Hypertension</i> , 2014, 32, 1359-1366.	0.3	758
99	A guide for easy- and difficult-to-treat hypertension. <i>International Journal of Cardiology</i> , 2014, 172, 17-22.	0.8	19
100	Does cardiovascular protection translate into renal protection?. <i>Nature Reviews Cardiology</i> , 2014, 11, 742-746.	6.1	14
101	High prevalence of masked uncontrolled hypertension in people with treated hypertension. <i>European Heart Journal</i> , 2014, 35, 3304-3312.	1.0	186
102	Renin-angiotensin system blockade: time for a reappraisal?. <i>European Heart Journal</i> , 2014, 35, 1703-1705.	1.0	2
103	Nocturnal Hypertension or Nondipping: Which Is Better Associated With the Cardiovascular Risk Profile?. <i>American Journal of Hypertension</i> , 2014, 27, 680-687.	1.0	106
104	Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 605-621.	0.9	51
105	Comparison of Agents That Affect Aldosterone Action. <i>Seminars in Nephrology</i> , 2014, 34, 285-306.	0.6	28
106	Spanish Society of Nephrology document on KDIGO guidelines for the assessment and treatment of chronic kidney disease. <i>Nefrologia</i> , 2014, 34, 302-16.	0.2	35
107	Dual neurohormonal intervention in CV disease: angiotensin receptor and Neprilysin inhibition. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 915-925.	1.9	23
108	The past, present and future of renin-angiotensin aldosterone system inhibition. <i>International Journal of Cardiology</i> , 2013, 167, 1677-1687.	0.8	97

#	ARTICLE	IF	CITATIONS
109	Differences Between Office and 24-Hour Blood Pressure Control in Hypertensive Patients With CKD: A 5,693-Patient Cross-sectional Analysis From Spain. <i>American Journal of Kidney Diseases</i> , 2013, 62, 285-294.	2.1	88
110	How can resistant hypertension be identified and prevented?. <i>Nature Reviews Cardiology</i> , 2013, 10, 293-296.	6.1	9
111	Long-term adherence to therapy: the clue to prevent hypertension consequences: Figure 1. <i>European Heart Journal</i> , 2013, 34, 2931-2932.	1.0	7
112	European Society of Hypertension Position Paper on Ambulatory Blood Pressure Monitoring. <i>Journal of Hypertension</i> , 2013, 31, 1731-1768.	0.3	1,124
113	Blood pressure control in CKD—still a matter of debate. <i>Nature Reviews Nephrology</i> , 2013, 9, 572-573.	4.1	11
114	Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. <i>European Heart Journal</i> , 2012, 33, 2782-2795.	1.0	148
115	Microalbuminuria breakthrough under chronic renin—angiotensin—aldosterone system suppression. <i>Journal of Hypertension</i> , 2012, 30, 204-209.	0.3	39
116	Ambulatory blood pressure monitoring and development of cardiovascular events in high-risk patients included in the Spanish ABPM registry. <i>Journal of Hypertension</i> , 2012, 30, 713-719.	0.3	97
117	Current challenges in the clinical management of hypertension. <i>Nature Reviews Cardiology</i> , 2012, 9, 267-275.	6.1	54
118	Clinical Features of 8295 Patients With Resistant Hypertension Classified on the Basis of Ambulatory Blood Pressure Monitoring. <i>Hypertension</i> , 2011, 57, 898-902.	1.3	696
119	Renal function and target organ damage in hypertension. <i>European Heart Journal</i> , 2011, 32, 1599-1604.	1.0	81
120	Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2011, 364, 907-917.	13.9	741
121	Validation of a therapeutic scheme for the treatment of resistant hypertension. <i>Journal of the American Society of Hypertension</i> , 2011, 5, 498-504.	2.3	21
122	Urinary Albumin Excretion Is Associated With Nocturnal Systolic Blood Pressure in Resistant Hypertensives. <i>Hypertension</i> , 2011, 57, 556-560.	1.3	51
123	Prevalence and Factors Associated With Circadian Blood Pressure Patterns in Hypertensive Patients. <i>Hypertension</i> , 2009, 53, 466-472.	1.3	312
124	Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension. <i>Journal of Hypertension</i> , 2009, 27, 673-679.	0.3	53
125	Renal and cardiovascular events: do they deserve the same consideration in clinical trials?. <i>Journal of Hypertension</i> , 2009, 27, 1743-1745.	0.3	5
126	European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. <i>Journal of Hypertension</i> , 2008, 26, 1505-1526.	0.3	707

#	ARTICLE	IF	CITATIONS
127	Effect of proteinuria and glomerular filtration rate on cardiovascular risk in essential hypertension. <i>Kidney International</i> , 2004, 66, S45-S49.	2.6	42
128	Renal function: the Cinderella of cardiovascular risk profile. <i>Journal of the American College of Cardiology</i> , 2001, 38, 1782-1787.	1.2	181
129	Renal Function and Intensive Lowering of Blood Pressure in Hypertensive Participants of the Hypertension Optimal Treatment (HOT) Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 218-225.	3.0	415
130	Renoprotection and Renin-Angiotensin System Blockade in Diabetes Mellitus. <i>American Journal of Hypertension</i> , 1997, 10, 325S-331S.	1.0	30
131	Blood pressure and renal function: therapeutic implications. <i>Journal of Hypertension</i> , 1996, 14, 1259-1263.	0.3	85
132	Antihypertensive Effect of Nitrendipine in the Hypertensive Patient with Renal Impairment. <i>Renal Failure</i> , 1993, 15, 359-363.	0.8	4